Focus is on Driving Commercial and Market Development Initiatives
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 14, 2013--
AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems for the treatment of atrial
fibrillation, or AF, and systems for the exclusion of the left atrial
appendage, today announced three promotions of personnel into key
Douglas J. Seith has been promoted to Senior Vice President of Sales
and Marketing and will be responsible for strengthening commercial
execution and market development in conjunction with expanding sales.
Doug has spent nine years at AtriCure and has over 25 years of cardiac
surgery, cardiology and general surgery sales and sales leadership
experience. Prior to joining AtriCure, Doug held leadership and/or
sales positions with A-Med/EmoblX, Inc., Heartport, Inc., Scimed Life
Systems, a division of Boston Scientific, Inc. and Automated
Instruments (a division of United States Surgical Corporation).
Michael Rogge has been promoted to Vice President of Marketing, and
under his expanded responsibility, will be focused on market
development activities and physician education programs that reach
newly redefined target markets. Mike has over 22 years of medical
device experience, the past seven with AtriCure building partnerships
with Key Opinion Leaders (KOLs) and leading customer-driven product
development initiatives to drive revenue growth. Prior to joining
AtriCure, Mr. Rogge held positions at Ethicon Endo-Surgery, a Johnson
& Johnson Company, Hill-Rom, and Baxter International.
M. Andrew Wade, CPA has been promoted to Vice President and Chief
Financial Officer. Andy has over 15 years of financial experience, the
past five with AtriCure building the finance and accounting team.
Prior to joining AtriCure, Andy held various financial positions with
Macy’s Inc., Saks Inc., and Arthur Andersen.
“I am looking forward to the continued contributions from Doug, Mike and
Andy in their new roles, each of whom has been instrumental to
AtriCure’s success to date. These promotions, combined with our focus in
building out our marketing and education initiatives along with our
continued international expansion under Pat Kennedy’s leadership, will
help us accelerate growth in the coming years,” said Mike Carrel,
President and Chief Executive Officer of AtriCure. “Additionally, Andy
provides great financial and operational discipline for AtriCure and we
anticipate a seamless transition into his expanded role as Chief
Mr. Carrel continued, “I am pleased with our growth in 2012 which was
driven by the strengths of our technology, product platforms and
customer relationships. As we enter 2013, I am confident in our ability
to further develop and expand our training and education program, and
position AtriCure to achieve its full potential, creating value for
customers and shareholders. I look forward to continuing to build our
team of talented and committed employees at AtriCure."
About AtriCure, Inc.
AtriCure, Inc. is a medical device company and a leader in developing,
manufacturing and selling innovative cardiac surgical ablation systems
designed to create precise lesions, or scars, in cardiac, or heart,
tissue for the treatment of atrial fibrillation, or AF, and systems for
the exclusion of the left atrial appendage. The Company believes
cardiothoracic surgeons are adopting its ablation products for the
treatment of AF during concomitant open-heart surgical procedures and
sole-therapy minimally invasive procedures. AF affects more than 5.5
million people worldwide and predisposes them to a five-fold increased
risk of stroke. The FDA has not cleared or approved certain AtriCure
products for the treatment of AF or a reduction in the risk of stroke.
This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements that address activities,
events or developments that AtriCure expects, believes or anticipates
will or may occur in the future, such as earnings estimates, other
predictions of financial performance, launches by AtriCure of new
products and market acceptance of AtriCure’s products. Forward-looking
statements are based on AtriCure’s experience and perception of current
conditions, trends, expected future developments and other factors it
believes are appropriate under the circumstances and are subject to
numerous risks and uncertainties, many of which are beyond AtriCure’s
control. These risks and uncertainties include the rate and degree of
market acceptance of AtriCure’s products, AtriCure’s ability to develop
and market new and enhanced products, the timing of and ability to
obtain and maintain regulatory clearances and approvals for its
products, the timing of and ability to obtain reimbursement of
procedures utilizing AtriCure’s products, competition from existing and
new products and procedures or AtriCure’s ability to effectively react
to other risks and uncertainties described from time to time in
AtriCure’s SEC filings, such as fluctuation of quarterly financial
results, reliance on third party manufacturers and suppliers, litigation
or other proceedings, government regulation and stock price volatility.
AtriCure does not guarantee any forward-looking statement, and actual
results may differ materially from those projected. AtriCure undertakes
no obligation to publicly update any forward-looking statement, whether
as a result of new information, future events or otherwise.
Source: AtriCure, Inc.
Andy Wade, Vice President and Chief
Financial Officer, 513-755-4564